Horizon Therapeutics (HZNP) Misses Q1 EPS by 13c, Offers FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Horizon Therapeutics (HZNP) Misses Q1 EPS by 13c, Offers FY Guidance

Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc

May 5, 2021 7:00 AM EDT

-- First-Quarter 2021 Net Sales of $342.4 Million; First-Quarter 2021 GAAP Net Loss of $123.4 Million; Adjusted EBITDA of $45.8 Million --

-- First-Quarter 2021 Orphan Segment Net Sales Increased 5 Percent to $257.5 Million; KRYSTEXXA® (pegloticase injection) First-Quarter 2021 Net Sales Increased 14 Percent to $106.7 Million --

-- Updating Full-Year 2021 Net Sales Guidance to $2.75 Billion to $2.85 Billion and Full-Year 2021 Adjusted EBITDA Guidance to $1.02 Billion to $1.06 Billion to Incorporate Viela, Acquired on March 15, 2021 --

-- Resumed Supply of TEPEZZA® (teprotumumab-trbw) in April Following U.S. FDA Approval of Increased Scale of Production... More